|
Bayer and Nuvisan create new research unit in Berlin
|
11 February 2020 |
|
Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery
|
09 January 2020 |
|
New set-up for IT at Bayer
|
12 December 2019 |
|
Bayer selects Pharmaron as partner organization
|
28 November 2019 |
|
Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases
|
14 November 2019 |
|
Bayer invests USD 50 Million in eGenesis Series B financing round
|
11 November 2019 |
|
Bayer launches LifeHub UK focused on artificial intelligence to optimize data-driven drug discovery and disease diagnosis
|
22 October 2019 |
|
Bayer inks deals with eleven startups under G4A Digital Health Partnerships program
|
10 October 2019 |
|
Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital open joint lab for research of new treatments for chronic lung diseases
|
24 September 2019 |
|
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
|
08 August 2019 |
|
LEO Pharma completes the acquisition of Bayer’s prescription dermatology business
|
02 July 2019 |
|
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial
|
21 June 2019 |
|
Bayer receives U.S. FDA breakthrough therapy designation for copanlisib for the treatment of marginal zone lymphoma
|
29 May 2019 |
|
Bayer reaches settlement to resolve Xarelto™ litigation
|
25 March 2019 |
|
Bayer is taking collaboration with health care start-ups to the next level
|
21 March 2019 |
|
Impact pioneers honored for groundbreaking ideas in the fields of healthcare and nutrition
|
07 March 2019 |
|
Bayer Thrombosis Research Award 2019 goes to Dr. Changjun Yin
|
28 February 2019 |
|
Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
|
15 February 2019 |
|
FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
|
03 December 2018 |
|
U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion
|
28 November 2018 |